SEER Cancer Statistics Review 1975-2007 National Cancer Institute

Devcan Version 6.5.0, April 2010, National Cancer Institute (http://srab.cancer.gov/devcan/).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,

Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

All Races Whites Blacks

Site Percent ( 95% C.I. ) Percent ( 95% C.I. ) Percent ( 95% C.I. )

All Sites 40.77 (40.67, 40.86 ) 41.23 (41.13, 41.34 ) 36.46 (36.17, 36.75 )

Invasive and In Situ 43.61 (43.51, 43.71 ) 44.13 (44.02, 44.24 ) 38.15 (37.86, 38.45 )

Oral Cavity and Pharynx 1.02 ( 1.01, 1.04 ) 1.05 ( 1.04, 1.07 ) 0.79 ( 0.75, 0.83 )

Esophagus 0.50 ( 0.49, 0.51 ) 0.52 ( 0.51, 0.53 ) 0.46 ( 0.43, 0.50 )

Stomach 0.88 ( 0.86, 0.89 ) 0.76 ( 0.75, 0.78 ) 1.12 ( 1.07, 1.17 )

Colon and Rectum 5.12 ( 5.09, 5.16 ) 5.09 ( 5.05, 5.13 ) 5.05 ( 4.94, 5.15 )

Invasive and In Situ 5.37 ( 5.33, 5.40 ) 5.32 ( 5.29, 5.36 ) 5.33 ( 5.22, 5.44 )

Liver and Intrahepatic Bile Duct 0.76 ( 0.75, 0.77 ) 0.65 ( 0.64, 0.67 ) 0.76 ( 0.73, 0.80 )

Pancreas 1.41 ( 1.39, 1.43 ) 1.40 ( 1.38, 1.42 ) 1.50 ( 1.44, 1.56 )

Larynx 0.36 ( 0.35, 0.37 ) 0.37 ( 0.36, 0.38 ) 0.46 ( 0.43, 0.49 )

Invasive and In Situ 0.39 ( 0.38, 0.40 ) 0.40 ( 0.39, 0.41 ) 0.48 ( 0.45, 0.51 )

Lung and Bronchus 6.95 ( 6.91, 6.99 ) 7.15 ( 7.11, 7.19 ) 6.53 ( 6.41, 6.65 )

Melanoma of the Skin 1.93 ( 1.91, 1.95 ) 2.24 ( 2.22, 2.27 ) 0.09 ( 0.07, 0.10 )

Invasive and In Situ 3.10 ( 3.08, 3.13 ) 3.55 ( 3.52, 3.58 ) 0.10 ( 0.09, 0.12 )

Breast 6.29 ( 6.26, 6.33 ) 6.47 ( 6.43, 6.51 ) 5.41 ( 5.30, 5.51 )

Invasive and In Situ 7.53 ( 7.49, 7.57 ) 7.71 ( 7.66, 7.75 ) 6.52 ( 6.40, 6.63 )

Urinary Bladder (Invasive and In Situ) 2.39 ( 2.37, 2.42 ) 2.59 ( 2.56, 2.62 ) 1.18 ( 1.13, 1.23 )

Kidney and Renal Pelvis 1.49 ( 1.47, 1.51 ) 1.55 ( 1.53, 1.57 ) 1.34 ( 1.29, 1.40 )

Brain and Other Nervous System 0.61 ( 0.59, 0.62 ) 0.66 ( 0.65, 0.68 ) 0.32 ( 0.29, 0.34 )

Thyroid 0.90 ( 0.89, 0.91 ) 0.94 ( 0.92, 0.95 ) 0.52 ( 0.49, 0.55 )

Hodgkin Lymphoma 0.23 ( 0.23, 0.24 ) 0.25 ( 0.24, 0.26 ) 0.20 ( 0.18, 0.22 )

Non-Hodgkin Lymphoma 2.10 ( 2.08, 2.12 ) 2.21 ( 2.19, 2.24 ) 1.20 ( 1.15, 1.25 )

Myeloma 0.64 ( 0.63, 0.65 ) 0.60 ( 0.59, 0.61 ) 1.05 ( 1.00, 1.10 )

Leukemia 1.30 ( 1.28, 1.31 ) 1.37 ( 1.35, 1.39 ) 0.82 ( 0.78, 0.87 )

Acute Lymphocytic Leukemia 0.13 ( 0.12, 0.13 ) 0.14 ( 0.13, 0.14 ) 0.07 ( 0.06, 0.08 )

Chronic Lymphocytic Leukemia 0.48 ( 0.47, 0.49 ) 0.51 ( 0.50, 0.52 ) 0.26 ( 0.24, 0.29 )

Acute Myeloid Leukemia 0.38 ( 0.37, 0.39 ) 0.39 ( 0.38, 0.40 ) 0.27 ( 0.24, 0.29 )

Chronic Myeloid Leukemia 0.16 ( 0.15, 0.16 ) 0.16 ( 0.16, 0.17 ) 0.12 ( 0.11, 0.14 )

Kaposi Sarcoma 0.05 ( 0.05, 0.05 ) 0.04 ( 0.04, 0.05 ) 0.08 ( 0.07, 0.10 )

Mesothelioma 0.12 ( 0.12, 0.13 ) 0.14 ( 0.13, 0.14 ) 0.06 ( 0.05, 0.07 )

Table 1.14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2005-2007
SEER Cancer Statistics Review 1975-2007 National Cancer Institute

Devcan Version 6.5.0, April 2010, National Cancer Institute (http://srab.cancer.gov/devcan/).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,

Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Note: Invasive cancer only unless specified otherwise.

a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area)

counties.

b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Asian/Pacific American Indian/

Islanders Alaska Nativesa Hispanicsb

Site Percent ( 95% C.I. ) Percent ( 95% C.I. ) Percent ( 95% C.I. )

All Sites 34.98 (34.60, 35.37 ) 27.78 (26.61, 29.09 ) 35.58 (35.24, 35.92 )

Invasive and In Situ 36.93 (36.55, 37.33 ) 29.00 (27.78, 30.35 ) 37.24 (36.89, 37.59 )

Oral Cavity and Pharynx 0.85 ( 0.80, 0.91 ) 0.66 ( 0.52, 1.00 ) 0.67 ( 0.63, 0.72 )

Esophagus 0.34 ( 0.30, 0.39 ) 0.46 ( 0.33, 0.80 ) 0.34 ( 0.31, 0.38 )

Stomach 1.90 ( 1.81, 2.00 ) 1.19 ( 0.93, 1.63 ) 1.43 ( 1.36, 1.50 )

Colon and Rectum 5.22 ( 5.06, 5.38 ) 4.15 ( 3.71, 4.75 ) 4.61 ( 4.48, 4.75 )

Invasive and In Situ 5.41 ( 5.25, 5.57 ) 4.36 ( 3.91, 4.96 ) 4.80 ( 4.67, 4.94 )

Liver and Intrahepatic Bile Duct 1.87 ( 1.78, 1.96 ) 1.00 ( 0.81, 1.37 ) 1.31 ( 1.25, 1.39 )

Pancreas 1.48 ( 1.39, 1.58 ) 1.19 ( 0.95, 1.60 ) 1.51 ( 1.43, 1.60 )

Larynx 0.15 ( 0.12, 0.18 ) 0.17 ( 0.10, 0.49 ) 0.27 ( 0.25, 0.30 )

Invasive and In Situ 0.16 ( 0.14, 0.19 ) 0.18 ( 0.10, 0.49 ) 0.29 ( 0.27, 0.33 )

Lung and Bronchus 5.55 ( 5.39, 5.72 ) 4.74 ( 4.23, 5.40 ) 4.12 ( 4.01, 4.25 )

Melanoma of the Skin 0.16 ( 0.14, 0.19 ) 0.36 ( 0.25, 0.68 ) 0.48 ( 0.44, 0.53 )

Invasive and In Situ 0.22 ( 0.19, 0.25 ) 0.55 ( 0.41, 0.89 ) 0.68 ( 0.63, 0.73 )

Breast 5.12 ( 5.00, 5.25 ) 3.57 ( 3.22, 4.08 ) 4.77 ( 4.66, 4.89 )

Invasive and In Situ 6.38 ( 6.24, 6.52 ) 4.09 ( 3.71, 4.61 ) 5.61 ( 5.50, 5.74 )

Urinary Bladder(Invasive and In Situ) 1.37 ( 1.29, 1.46 ) 0.72 ( 0.55, 1.07 ) 1.49 ( 1.41, 1.57 )

Kidney and Renal Pelvis 0.95 ( 0.89, 1.02 ) 1.68 ( 1.44, 2.09 ) 1.55 ( 1.49, 1.62 )

Brain and Other Nervous System 0.40 ( 0.36, 0.45 ) 0.34 ( 0.25, 0.65 ) 0.53 ( 0.49, 0.57 )

Thyroid 0.98 ( 0.93, 1.03 ) 0.45 ( 0.35, 0.76 ) 0.81 ( 0.77, 0.86 )

Hodgkin Lymphoma 0.12 ( 0.10, 0.15 ) 0.07 ( 0.04, 0.39 ) 0.23 ( 0.21, 0.26 )

Non-Hodgkin Lymphoma 1.68 ( 1.60, 1.78 ) 1.22 ( 1.00, 1.62 ) 1.99 ( 1.91, 2.07 )

Myeloma 0.49 ( 0.44, 0.55 ) 0.50 ( 0.30, 0.90 ) 0.64 ( 0.59, 0.69 )

Leukemia 0.84 ( 0.78, 0.91 ) 0.59 ( 0.46, 0.92 ) 1.02 ( 0.97, 1.08 )

Acute Lymphocytic Leukemia 0.11 ( 0.09, 0.14 ) 0.07 ( 0.04, 0.38 ) 0.19 ( 0.17, 0.21 )

Chronic Lymphocytic Leukemia 0.15 ( 0.12, 0.19 ) 0.12 ( 0.07, 0.44 ) 0.23 ( 0.20, 0.27 )

Acute Myeloid Leukemia 0.38 ( 0.34, 0.43 ) 0.23 ( 0.15, 0.54 ) 0.32 ( 0.29, 0.35 )

Chronic Myeloid Leukemia 0.10 ( 0.09, 0.13 ) 0.10 ( 0.05, 0.42 ) 0.14 ( 0.12, 0.17 )

Kaposi Sarcoma 0.02 ( 0.01, 0.04 ) 0.03 ( 0.01, 0.35 ) 0.09 ( 0.07, 0.11 )

Mesothelioma 0.05 ( 0.04, 0.07 ) 0.07 ( 0.03, 0.38 ) 0.12 ( 0.10, 0.15 )

Table 1.14 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2005-2007